1. Home
  2. DXLG vs RFL Comparison

DXLG vs RFL Comparison

Compare DXLG & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Destination XL Group Inc.

DXLG

Destination XL Group Inc.

HOLD

Current Price

$1.14

Market Cap

49.6M

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.46

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXLG
RFL
Founded
1976
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Real Estate
Sector
Consumer Discretionary
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
49.6M
54.4M
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
DXLG
RFL
Price
$1.14
$1.46
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.50
N/A
AVG Volume (30 Days)
223.2K
143.0K
Earning Date
12-11-2025
12-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$442,120,000.00
$1,029,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
47.63
52 Week Low
$0.88
$1.17
52 Week High
$3.10
$3.19

Technical Indicators

Market Signals
Indicator
DXLG
RFL
Relative Strength Index (RSI) 53.70 64.11
Support Level $1.01 $1.21
Resistance Level $1.58 $1.60
Average True Range (ATR) 0.15 0.08
MACD 0.04 0.04
Stochastic Oscillator 35.77 67.44

Price Performance

Historical Comparison
DXLG
RFL

About DXLG Destination XL Group Inc.

Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: